However, increasing the hydrodynamic size of the insulin, such asinsulin peglispro (103), or bindingacylated insulins to HSA, such as IDeg (104), can eliminate the need for insulin dose adjustments in diabetes patientswith CKD. The gene discussed is INS; the disease is chronic kidney disease.